Autoimmune Diseases

Systemic Lupus Erythematosus


Publishing date
21 Sep 2012
Status
Published
Submission deadline
04 May 2012

Lead Editor

1Minami-Otsuka Institute of Technology, Minami-Otsuka Clinic, 2-41-9 Minami-Otsuka, Toshima-ku, Tokyo 170-0005 Japan

2Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain

3Division of Rheumatology and Clinical Immunology, School of Medicine, Jichi Medical University, 3311 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

4Faculty of Biomedical Engineering, Toin University of Yokohama, 1614 Kurogane-machi, Aoba-ku, Yokohama 225-8802, Japan

5Department of Immunology and Rheumatology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Vasco de Quiroga 15, Colonia Sección XVI, 14000 Mexico City, DF, Mexico


Systemic Lupus Erythematosus

Description

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by widespread immunologic abnormalities and multiorgan involvement including the skin, joints, and the peripheral and central nervous systems, amongst other organs and systems. The clinical course of SLE is usually dependent on the organ involved such as neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE), lupus nephritis (LN), lupus pancreatitis (LP), and pulmonary hypertension (PH). Early diagnosis and epoch-making therapeutic strategies are prerequisites for improved prognosis of patients with SLE. To fulfill this medical need, a better understanding of the pathogenesis of SLE is required. Research over the course of several years has yielded a basic scientific understanding of SLE pathogenesis. This includes understanding the role of various cytokines and chemokines in disease progression, the chronic activation of plasmacytoid dendritic cells by circulating immune complexes, and the expression of neutrophil-specific genes.

The main focus of this special issue will be on the diagnostic tools for specific organ involvement in SLE (NPSLE, LN, LP, PH, etc.) and on the development of new therapeutic strategies (biologics, etc.), as well as the pathogenesis of SLE, including animal models of SLE. This special issue will become an international forum for researchers and clinicians to summarize the most recent developments and ideas in the field.

We invite investigators to contribute original research as well as review articles. Potential topics include, but are not limited to:

  • Immunological pathogenesis of lupus: roles of activation of plasmacytoid dendritic cells by circulating immune complex NKT cells, invariant NKT cells, autoantibodies, and autoantigens in the pathogenesis of lupus
  • Early diagnostic tools for NPSLE, LN, LP, and PH: intrathecal cytokines, chemokines, and autoantibodies
  • Therapeutic strategies for lupus: immunosuppressants (cyclophosphamide and mycophenolate mofetil (MMF)), biologics (anti-CD20 antibody and BLyS-specific inhibitor), and so forth
  • Genetic approach in the pathogenesis of lupus and murine models for lupus: MHC genes, genes encoding complement components, TNF, FcγR, T cell receptors, and cytokines

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Autoimmune Diseases
 Journal metrics
See full report
Acceptance rate-
Submission to final decision-
Acceptance to publication-
CiteScore4.600
Journal Citation Indicator0.400
Impact Factor4.0
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.